Siegfried Holding Valuation
Is SFZN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SFZN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: SFZN (CHF1132) is trading above our estimate of fair value (CHF891.88)
Significantly Below Fair Value: SFZN is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SFZN?
Other financial metrics that can be useful for relative valuation.
What is SFZN's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CHF 4.86b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.1x |
Enterprise Value/EBITDA | 19.6x |
PEG Ratio | 2.8x |
Price to Earnings Ratio vs Peers
How does SFZN's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 52.4x | ||
BANB Bachem Holding | 50.6x | 18.7% | CHF 5.8b |
TECN Tecan Group | 35.9x | 15.6% | CHF 3.6b |
SKAN SKAN Group | 54.7x | 20.1% | CHF 1.8b |
LONN Lonza Group | 68.5x | 24.7% | CHF 39.2b |
SFZN Siegfried Holding | 37.7x | 13.6% | CHF 4.9b |
Price-To-Earnings vs Peers: SFZN is good value based on its Price-To-Earnings Ratio (37.7x) compared to the peer average (52.4x).
Price to Earnings Ratio vs Industry
How does SFZN's PE Ratio compare vs other companies in the European Life Sciences Industry?
Price-To-Earnings vs Industry: SFZN is good value based on its Price-To-Earnings Ratio (37.7x) compared to the European Life Sciences industry average (42.5x).
Price to Earnings Ratio vs Fair Ratio
What is SFZN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 37.7x |
Fair PE Ratio | 23.6x |
Price-To-Earnings vs Fair Ratio: SFZN is expensive based on its Price-To-Earnings Ratio (37.7x) compared to the estimated Fair Price-To-Earnings Ratio (23.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | CHF 1,132.00 | CHF 1,126.92 -0.4% | 13.1% | CHF 1,500.00 | CHF 900.00 | n/a | 13 |
Sep ’25 | CHF 1,118.00 | CHF 1,075.15 -3.8% | 7.8% | CHF 1,188.00 | CHF 900.00 | n/a | 13 |
Aug ’25 | CHF 1,024.00 | CHF 1,041.00 +1.7% | 8.9% | CHF 1,188.00 | CHF 880.00 | n/a | 12 |
Jul ’25 | CHF 944.00 | CHF 1,015.90 +7.6% | 7.4% | CHF 1,125.00 | CHF 880.00 | n/a | 10 |
Jun ’25 | CHF 899.00 | CHF 1,015.90 +13.0% | 7.4% | CHF 1,125.00 | CHF 880.00 | n/a | 10 |
May ’25 | CHF 882.00 | CHF 1,015.90 +15.2% | 7.4% | CHF 1,125.00 | CHF 880.00 | n/a | 10 |
Apr ’25 | CHF 921.00 | CHF 1,005.36 +9.2% | 7.8% | CHF 1,125.00 | CHF 880.00 | n/a | 11 |
Mar ’25 | CHF 905.00 | CHF 964.55 +6.6% | 7.2% | CHF 1,050.00 | CHF 820.00 | n/a | 11 |
Feb ’25 | CHF 846.00 | CHF 911.60 +7.8% | 8.4% | CHF 1,000.00 | CHF 800.00 | n/a | 10 |
Jan ’25 | CHF 859.50 | CHF 891.22 +3.7% | 7.5% | CHF 990.00 | CHF 800.00 | n/a | 9 |
Dec ’24 | CHF 782.50 | CHF 881.88 +12.7% | 7.4% | CHF 990.00 | CHF 800.00 | n/a | 8 |
Nov ’24 | CHF 714.50 | CHF 881.88 +23.4% | 7.4% | CHF 990.00 | CHF 800.00 | n/a | 8 |
Oct ’24 | CHF 784.50 | CHF 871.88 +11.1% | 7.8% | CHF 990.00 | CHF 800.00 | n/a | 8 |
Sep ’24 | CHF 789.00 | CHF 860.56 +9.1% | 11.8% | CHF 990.00 | CHF 640.00 | CHF 1,118.00 | 9 |
Aug ’24 | CHF 769.50 | CHF 817.50 +6.2% | 11.9% | CHF 945.00 | CHF 640.00 | CHF 1,024.00 | 8 |
Jul ’24 | CHF 739.00 | CHF 813.13 +10.0% | 12.0% | CHF 945.00 | CHF 640.00 | CHF 944.00 | 8 |
Jun ’24 | CHF 734.00 | CHF 815.00 +11.0% | 12.7% | CHF 945.00 | CHF 640.00 | CHF 899.00 | 7 |
May ’24 | CHF 686.50 | CHF 805.00 +17.3% | 12.2% | CHF 945.00 | CHF 640.00 | CHF 882.00 | 7 |
Apr ’24 | CHF 671.50 | CHF 819.29 +22.0% | 13.0% | CHF 945.00 | CHF 640.00 | CHF 921.00 | 7 |
Mar ’24 | CHF 666.00 | CHF 838.88 +26.0% | 13.4% | CHF 971.00 | CHF 640.00 | CHF 905.00 | 8 |
Feb ’24 | CHF 674.50 | CHF 869.50 +28.9% | 9.3% | CHF 971.00 | CHF 700.00 | CHF 846.00 | 8 |
Jan ’24 | CHF 613.50 | CHF 869.50 +41.7% | 9.3% | CHF 971.00 | CHF 700.00 | CHF 859.50 | 8 |
Dec ’23 | CHF 645.50 | CHF 869.50 +34.7% | 9.3% | CHF 971.00 | CHF 700.00 | CHF 782.50 | 8 |
Nov ’23 | CHF 605.50 | CHF 904.19 +49.3% | 6.7% | CHF 995.50 | CHF 825.00 | CHF 714.50 | 8 |
Oct ’23 | CHF 735.00 | CHF 934.13 +27.1% | 7.1% | CHF 1,050.00 | CHF 840.00 | CHF 784.50 | 8 |
Sep ’23 | CHF 737.50 | CHF 909.67 +23.3% | 7.4% | CHF 1,050.00 | CHF 840.00 | CHF 789.00 | 9 |
Analyst Forecast: Target price is lower than the current share price.